AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02066792 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
Study NCT02066792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
Study NCT02472847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
Study NCT02472847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
Study NCT01113151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mablet (Magnesium-supplement)
Description: 3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
Study NCT01113151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo tablets daily for 12 weeks
Study NCT04022382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
Study NCT03462095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Description: After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
Study NCT03269981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole breast irradiation
Description: Radiotherapy to the whole breast alone.
Study NCT03269981 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast and nodal irradiation
Description: Radiotherapy to the whole breast and regional lymph nodes.
Study NCT02407093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training
Description: Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
Study NCT02407093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Army Physical Readiness Training
Description: Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
Study NCT04148274 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study NCT02723201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 Captisol Oral Solution
Description: TAK-020 solution.
Study NCT02723201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 CCT
Description: TAK-020 co-crystal tablet
Study NCT02723201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 SDT
Description: TAK-020 Solid dispersion tablet.
Study NCT02815527 — intervention group
Intervention type: OTHER
Intervention: Fresubin intensive
Description: Enteral nutrition containing a high protein concentration
Study NCT03432247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Music Therapy
Description: Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
Study NCT03432247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal support
Description: Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
Study NCT02723201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 IRT
Description: TAK-020 immediate release tablet.
Study NCT02723201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 CCT
Description: TAK-020 co-crystal tablet.
Study NCT02723201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 Solid Formulation
Description: TAK-020 solid formulation
Study NCT00425672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONTAK
Description: Given IV
Study NCT00425672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00425672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00425672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT00425672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01012674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOF MRA
Description: Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
Study NCT00425672 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study NCT01836341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT01836341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01836341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01836341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT01836341 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT01112280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap-assisted chromoendoscopy
Description: A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
Study NCT02678286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Study NCT02678286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study NCT03725605 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LTX-315 and TILs
Description: Intratumoural injection of LTX-315 and infusion of TILs
Study NCT00840138 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical reconstruction
Description: Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube
Study NCT02819934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD101
Description: after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
Study NCT02731365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
Study NCT02438722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO
Study NCT02438722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib Dimaleate
Description: Given PO
Study NCT03588741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa
Description: Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month.
Study NCT01650870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline Lactulose
Study NCT01650870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalline Lactulose
Study NCT00984620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335
Study NCT00984620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha
Study NCT00984620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV)
Study NCT00662532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl
Description: 1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
Study NCT02438722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT02438722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02438722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03236753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thread-embedding Acupuncture (TEA)
Description: The acupoints and size of TEA are as follows:~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~3. Both BL25: transverse insertion toward iliac crest, 4cm~4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm~6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm~8. Both GB30: perpendicular insertion, 6cm~9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm
Study NCT03236753 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Thread-embedding Acupuncture (STEA)
Description: All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
Study NCT03124420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
Study NCT03124420 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lansoprazole
Description: Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
Study NCT03124420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
Study NCT03124420 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Amoxicillin
Description: Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
Study NCT03124420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
Study NCT03124420 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Clarithromycin
Description: Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
Study NCT00354198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
Study NCT00354198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
Study NCT00354198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
Study NCT05713994 — intervention group
Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab plus Atezolizumab
Description: Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab Biosimilar IBI305 plus sintilimab
Description: Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: 8mg; p.o.; q.d.
Study NCT03728283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement in combination with connective tissue grafting
Description: A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: 400mg; p.o. bid
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Donafenib
Description: 200mg; p.o. bid
Study NCT03728283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implants were placed following teh manufacturer's instructions
Study NCT01290796 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ajust Adjustable Single-Incision Sling
Description: The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
Study NCT03087617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imbio Smoking Cessation Report
Description: Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
Study NCT03087617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 45 minute counseling session with a tobacco treatment specialist.
Study NCT03087617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: 45 minute counseling session with a tobacco treatment specialist.
Study NCT03087617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care for Lung Cancer Screening patients.
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Regorafenib
Description: 160 mg; p.o.; q.d.
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: apatinib plus camrelizumab
Description: Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
Study NCT05713994 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Study NCT01597063 — intervention group
Intervention type: DEVICE
Intervention: SEQureDx Trisomy Test
Description: Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
Study NCT01946178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirabilis High-Intensity Focused Ultrasound Treatment System
Description: The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
Study NCT02493348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmic Sensory Stimulation
Description: Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
Study NCT02493348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Sensory Stimulation
Description: Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
Study NCT00006227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV